HESTERBIOBSEHester Biosciences LtdHighPositive
Announced Fri, 15 May · 12:00 IST

Board of Directors Recommended Final Dividend of INR 11 per share for the FY 2025-26, Subject to approval of Shareholders

Corporate Actions View source PDF

HESTERBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+1.6%1-day move
₹1749.00
prior close
₹1973.80
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.2-0.9-1.1-0.7+1.6+3.8+5.2+7.8+8.2+21.8+11.7+18.8+37.4
Up moveDown movePending
AI summary

Hester Biosciences Board has recommended a final dividend of INR 11 per equity share (110% on INR 10 face value) for FY 2025-26, subject to shareholder approval at the AGM. For FY26, standalone profit after tax surged 63.6% to INR 521 million from INR 318.42 million in FY25, while consolidated profit nearly doubled to INR 574.84 million from INR 288.26 million. Standalone revenue grew modestly to INR 2,921.36 million from INR 2,864.66 million. The company also divested its 43.81% stake in subsidiary Texas Lifescience Private Limited in March 2026. Ms. Priya Gandhi, daughter of CEO Rajiv Gandhi, was reappointed as Executive Director for 3 years from October 2026.

Likely market impact

The strong profit growth and dividend recommendation signal company health and shareholder returns. Investors holding shares before the record date will receive INR 11 per share if approved at the AGM.